10-Sep-2026
TipRanks (Tue, 8-Sep 9:10 AM ET)
Tonix Pharma Appoints New Chief Commercial Officer
TipRanks (Tue, 8-Sep 7:29 AM ET)
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
Market Chameleon (Mon, 10-Aug 7:16 AM ET)
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ stock market under the symbol TNXP.
As of September 10, 2026, TNXP stock price declined to $12.28 with 280,131 million shares trading.
TNXP has a beta of 1.11, meaning it tends to be more sensitive to market movements. TNXP has a correlation of 0.04 to the broad based SPY ETF.
TNXP has a market cap of $210.61 million. This is considered a Small Cap stock.
Last quarter Tonix Pharmaceuticals Holding Corp. reported $14 million in Revenue and -$2.44 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.20.
In the last 3 years, TNXP traded as high as $2,976.00 and as low as $6.76.
The top ETF exchange traded funds that TNXP belongs to (by Net Assets): VTI, FESM, VXF, VTWO, PRFZ.
TNXP has underperformed the market in the last year with a price return of -52.4% while the SPY ETF gained +17.7%. However, in the short term, TNXP had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.2% vs +3.1% return in SPY. But in the last 2 weeks, TNXP shares have been beat by the market, returning -10.0% compared to an SPY return of -1.1%.
TNXP support price is $12.32 and resistance is $13.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNXP shares will trade within this expected range on the day.